Modality
Small Molecule
MOA
Menini
Target
GLP-1R
Pathway
Amyloid
CML
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Feb 2029
Phase 2Current
NCT05890451
278 pts·CML
2024-01→2026-08·Recruiting
NCT06084216
1,467 pts·CML
2017-04→2029-02·Recruiting
1,745 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-114mo awayPh2 Data· CML
2029-02-282.9y awayPh2 Data· CML
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2026-08-11 · 4mo away
CML
Ph2 Data
2029-02-28 · 2.9y away
CML
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05890451 | Phase 2 | CML | Recruiting | 278 | ORR |
| NCT06084216 | Phase 2 | CML | Recruiting | 1467 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Mavuglumide | Bayer | Approved | GLP-1R |